Relmada Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de Relmada Therapeutics es Sergio Traversa , nombrado en Apr 2012, tiene una permanencia de 12.58 años. compensación anual total es $4.78M, compuesta por 14.7% salario y 85.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.27% de las acciones de la empresa, por valor de $1.06M. La antigüedad media del equipo directivo y de la junta directiva es de 4.8 años y 4.8 años, respectivamente.
Información clave
Sergio Traversa
Chief Executive Officer (CEO)
US$4.8m
Compensación total
| Porcentaje del salario del CEO | 14.7% |
| Permanencia del CEO | 12.6yrs |
| Participación del CEO | 1.3% |
| Permanencia media de la dirección | 4.8yrs |
| Promedio de permanencia en la Junta Directiva | 4.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Relmada Therapeutics: Run Up Into Results May Resume Following This Drop
Mar 21Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Mar 13
Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark
Jan 14Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
Dec 04Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
Aug 29We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
May 07We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Dec 15Relmada Downgraded at Truist, Guggenheim in wake of depression candidate failure
Oct 14Relmada Therapeutics: Initiating With A Strong BUY; Key Phase 3 Short-Term Catalysts Lined Up
Sep 14Relmada Therapeutics receives FDA fast track tag for REL-1017 to treat depression
Aug 09We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely
Jul 14Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
Feb 264 Clinical Catalysts On Tap For Relmada In 2022
Jan 28Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
Nov 04Our First Look At Relmada Therapeutics
Jun 28We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Jun 28Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Mar 09What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?
Jan 15
Enrollment underway in Relmada Therapeutics' late-stage depression study with REL-1017
Dec 07Relmada Therapeutics (RLMD) Investor Presentation - Slideshow
Dec 02Relmada Therapeutics (RLMD) Investor Presentation - Slideshow
Nov 16Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$86m |
| Jun 30 2024 | n/a | n/a | -US$87m |
| Mar 31 2024 | n/a | n/a | -US$94m |
| Dec 31 2023 | US$5m | US$701k | -US$99m |
| Sep 30 2023 | n/a | n/a | -US$112m |
| Jun 30 2023 | n/a | n/a | -US$129m |
| Mar 31 2023 | n/a | n/a | -US$144m |
| Dec 31 2022 | US$3m | US$668k | -US$157m |
| Sep 30 2022 | n/a | n/a | -US$153m |
| Jun 30 2022 | n/a | n/a | -US$157m |
| Mar 31 2022 | n/a | n/a | -US$143m |
| Dec 31 2021 | US$36m | US$630k | -US$126m |
| Sep 30 2021 | n/a | n/a | -US$112m |
| Jun 30 2021 | n/a | n/a | -US$86m |
| Mar 31 2021 | n/a | n/a | -US$71m |
| Dec 31 2020 | US$900k | US$600k | -US$59m |
| Sep 30 2020 | n/a | n/a | -US$43m |
| Jun 30 2020 | n/a | n/a | -US$30m |
| Mar 31 2020 | n/a | n/a | -US$23m |
| Dec 31 2019 | US$16m | US$214k | -US$15m |
| Sep 30 2019 | n/a | n/a | -US$18m |
| Jun 30 2019 | n/a | n/a | -US$17m |
| Mar 31 2019 | n/a | n/a | -US$17m |
| Dec 31 2018 | n/a | n/a | -US$17m |
| Sep 30 2018 | n/a | n/a | -US$11m |
| Jun 30 2018 | US$975k | US$376k | -US$9m |
Compensación vs. Mercado: La compensación total de Sergio($USD4.78M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD647.72K).
Compensación vs. Ingresos: La compensación de Sergio ha aumentado mientras la empresa no es rentable.
CEO
Sergio Traversa (64 yo)
12.6yrs
Permanencia
US$4,778,944
Compensación
Dr. Sergio Traversa, PharmD, MBA has been the Chief Executive Officer and a Director of Relmada Therapeutics, Inc. since April 18, 2012. Dr. Traversa served as Interim Chief Financial Officer at Relmada Th...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 12.6yrs | US$4.78m | 1.27% $ 1.1m | |
| Chief Financial Officer | 4.8yrs | US$2.34m | 0.29% $ 243.8k | |
| Chief Accounting & Compliance Officer | 4.8yrs | US$2.33m | 0.13% $ 107.6k | |
| Chief Scientific Officer | 4.1yrs | sin datos | sin datos | |
| VP & Head of Clinical Operations | 5.6yrs | sin datos | sin datos | |
| Chief Clinical Officer | 4.1yrs | sin datos | sin datos | |
| Head of Commercial | 2.3yrs | sin datos | sin datos | |
| Senior Clinical Development Advisor | no data | sin datos | sin datos | |
| Consultant | 7.6yrs | sin datos | sin datos |
4.8yrs
Permanencia media
63yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de RLMD se considera experimentado (4.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 12.6yrs | US$4.78m | 1.27% $ 1.1m | |
| Chief Financial Officer | 4.8yrs | US$2.34m | 0.29% $ 243.8k | |
| Independent Chairman of the Board | 9.3yrs | US$674.90k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.8yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 7.4yrs | sin datos | sin datos | |
| Independent Director | 1.8yrs | US$1.33m | 0% $ 0 | |
| Director | 9yrs | US$1.67m | 0.70% $ 585.9k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 4.9yrs | US$604.77k | sin datos | |
| Member of Scientific Advisory Board | 4.8yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 4.8yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 4.8yrs | sin datos | sin datos |
4.8yrs
Permanencia media
62.5yo
Promedio de edad
Junta con experiencia: La junta directiva de RLMD se considera experimentada (4.8 años de antigüedad promedio).